ATE262909T1 - Intravenöse alendronatformulierungen - Google Patents

Intravenöse alendronatformulierungen

Info

Publication number
ATE262909T1
ATE262909T1 AT95929625T AT95929625T ATE262909T1 AT E262909 T1 ATE262909 T1 AT E262909T1 AT 95929625 T AT95929625 T AT 95929625T AT 95929625 T AT95929625 T AT 95929625T AT E262909 T1 ATE262909 T1 AT E262909T1
Authority
AT
Austria
Prior art keywords
intravenous
bone disease
alendronate formulations
formulations
intravenous alendronate
Prior art date
Application number
AT95929625T
Other languages
English (en)
Inventor
Gerald S Brenner
Musa M Ghannam
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE262909T1 publication Critical patent/ATE262909T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95929625T 1994-08-24 1995-08-21 Intravenöse alendronatformulierungen ATE262909T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/296,192 US5780455A (en) 1994-08-24 1994-08-24 Intravenous alendronate formulations
PCT/US1995/010583 WO1996005842A1 (en) 1994-08-24 1995-08-21 Intravenous alendronate formulations

Publications (1)

Publication Number Publication Date
ATE262909T1 true ATE262909T1 (de) 2004-04-15

Family

ID=23140992

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95929625T ATE262909T1 (de) 1994-08-24 1995-08-21 Intravenöse alendronatformulierungen

Country Status (10)

Country Link
US (3) US5780455A (de)
EP (1) EP0777484B1 (de)
JP (2) JP3962429B2 (de)
AT (1) ATE262909T1 (de)
AU (1) AU698411B2 (de)
CA (1) CA2197210C (de)
DE (1) DE69532810T2 (de)
ES (1) ES2216017T3 (de)
PT (1) PT777484E (de)
WO (1) WO1996005842A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0641325B1 (de) * 1992-05-21 2001-03-07 Monsanto Company Inhibitoren retroviraler proteasen
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
PL332496A1 (en) * 1996-10-04 1999-09-13 Merck & Co Inc Liquid alendronate preparations
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
US6794536B1 (en) 1998-12-10 2004-09-21 Aesqen, Inc. Method for preparation of disodium pamidronate
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
IL150841A0 (en) * 2000-02-09 2003-02-12 Hokuriku Pharmaceutical 1h-imidazopyridine derivatives
EP1284754B1 (de) * 2000-05-05 2006-01-04 F. Hoffmann-La Roche Ag Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze
AU9259801A (en) * 2000-09-14 2002-03-26 Merck & Co Inc Alpha v integrin receptor antagonists
EP1318818A4 (de) * 2000-09-18 2004-09-29 Faulding F H & Co Ltd Diphosphonat-lösungen
US8721625B2 (en) * 2001-01-26 2014-05-13 Cook Medical Technologies Llc Endovascular medical device with plurality of wires
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
AT502590A1 (de) * 2001-09-27 2007-04-15 Oekopharm Forschungs Und Entwi Basenhältige mikronährstoffmischung
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
WO2006019843A1 (en) * 2004-07-15 2006-02-23 Nanobac Life Sciences Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
US20060204567A1 (en) * 2005-03-08 2006-09-14 Jiang Hu Potato proteinase inhibitor II exhibits activity in elevating fasting plasma cholecystokinin concentrations
US7605148B2 (en) * 2007-04-16 2009-10-20 Aurobindo Pharma Ltd. Aqueous oral solution of bisphosphonic acid
US20100286038A1 (en) * 2007-09-21 2010-11-11 Valentyn Antochshuk Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
US20110065672A1 (en) * 2009-09-16 2011-03-17 Mount Sinai School Of Medicine Of New York University Bisphosphonate-prostatic acid phosphatase inhibitor conjugates to treat prostate cancer bone metastasis
EP2363111A1 (de) * 2010-03-01 2011-09-07 Combino Pharm, S.L. Stabile pharmazeutische Zusammensetzung mit Bisphosphonat
US9682090B2 (en) 2014-11-14 2017-06-20 University Of Washington Methods for treating and preventing prostate cancer bone metastases
US20240091181A1 (en) * 2020-12-29 2024-03-21 Next Science IP Holdings Pty Ltd Cancer treatment composition and method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06700B2 (ja) * 1986-03-27 1994-01-05 旭化成工業株式会社 安定な水性液剤
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
JP2617508B2 (ja) * 1988-02-05 1997-06-04 エーザイ株式会社 安定なジフェンヒドラミン含有水溶液
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
JP2974722B2 (ja) * 1990-04-03 1999-11-10 帝国臓器製薬株式会社 カルシトニン注射液
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
WO1994014455A1 (en) * 1992-12-23 1994-07-07 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations

Also Published As

Publication number Publication date
US5780455A (en) 1998-07-14
CA2197210C (en) 2008-02-19
AU3332095A (en) 1996-03-14
JP3962429B2 (ja) 2007-08-22
EP0777484A4 (de) 1998-08-05
ES2216017T3 (es) 2004-10-16
EP0777484A1 (de) 1997-06-11
US5843924A (en) 1998-12-01
DE69532810T2 (de) 2005-02-17
EP0777484B1 (de) 2004-03-31
JP2004075690A (ja) 2004-03-11
US5914323A (en) 1999-06-22
CA2197210A1 (en) 1996-02-29
WO1996005842A1 (en) 1996-02-29
DE69532810D1 (de) 2004-05-06
JP4177208B2 (ja) 2008-11-05
AU698411B2 (en) 1998-10-29
PT777484E (pt) 2004-06-30
JPH10504574A (ja) 1998-05-06

Similar Documents

Publication Publication Date Title
DE69532810D1 (de) Intravenöse alendronatformulierungen
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
DK1123094T3 (da) Terapeutiske præparater (II)
DK0759757T3 (da) Orale, væskeformige alendronatformuleringer
YU25295A (sh) Primena alendronata u proizvodnji leka za sprečavanja periproteznog gubitka kosti kod pacijenata sa ortopedskim implantiranim sredstvima
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
NO20034684D0 (no) Innretning for administrering av midler gjennom stratum corcum
EP1064000A4 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
RU94031209A (ru) Применение бисфосфонатов и гормона околощитовидной железы для лечения остеопороза
DE69921650D1 (de) Patientenspezifische dosimetrie
DE69634357D1 (de) Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
EA200201258A1 (ru) Способ лучевой терапии
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
SE8704248D0 (sv) Medical use
DE69814394D1 (de) Verwendung von levobupivacain
BG104797A (en) Use of dexmedetomi dine for sedative effect in patients in an intensive care unit
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
ATE185274T1 (de) Therapeutisches mittel gegen drohenden abortus
SE9101341D0 (sv) New medicinal use
FR2635006B1 (fr) Medicament destine a regulariser les secretions hormonales et a traiter la sterilite
UA10221A (uk) Спосіб лікування рецидивного бронхіту у дітей
ATE328604T1 (de) Verwendung von wachstumshormon in niederen dosen
UA10335A (uk) Спосіб корекції порушеhь обміhу кальцію у хворих hа сиhдром рейтера хламідійhої етіології

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0777484

Country of ref document: EP

REN Ceased due to non-payment of the annual fee